Core Insights - Samsung Biologics received the Sustainability Leadership Award at the 2026 CDMO Leadership Awards, recognizing its commitment to sustainable practices across operations and value chain [1][2] - The company was also named "Best in Class" in Cultural Fit in the 'Biologics—Large CDMOs' category, highlighting its strong partnerships with clients [1] Awards and Recognition - The CDMO Leadership Awards evaluate top-performing service providers based on global client feedback in areas such as facilities, innovation, and manufacturing capabilities [2] - Samsung Biologics has consistently been recognized for reliable execution and service quality, supported by strong client feedback [2] Sustainability Efforts - Sustainability is a core value for Samsung Biologics, guiding its business practices and partnerships [4] - The company achieved a Platinum rating from EcoVadis for its sustainability practices and implemented a validated product carbon footprint (PCF) system for emissions measurement [4] Manufacturing Capacity and Expansion - Samsung Biologics has a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II, with an additional 60,000 liters from a planned acquisition in Rockville, Maryland [6] - The company has secured land for Bio Campus III to support future capacity expansion for next-generation therapies [6] Technological Advancements - Samsung Biologics utilizes advanced technologies to develop diverse modalities, including multispecific antibodies and mRNA therapeutics [7] - The ExellenS™ framework is implemented across its manufacturing network to ensure standardized designs and processes [7] Global Network - Samsung Biologics operates a global manufacturing and commercial network across Korea, the U.S., and Japan, with dedicated support for clients in various regions [9] Commitment to Quality - The company is dedicated to the on-time, in-full delivery of safe, high-quality biomedicines while making sustainable business decisions for societal and global health improvement [10]

Core Insights - Samsung Biologics has announced the acquisition of 100% of Human Genome Sciences from GSK for USD 280 million, marking its first U.S.-based manufacturing site and expanding its global footprint [1][3][7] - The Rockville facility includes two cGMP manufacturing plants with a combined capacity of 60,000 liters, supporting both clinical and commercial production [2][3] - The acquisition will retain over 500 employees at the site, ensuring operational continuity and stability [3] Company Expansion - The acquisition is part of Samsung Biologics' strategy to enhance its manufacturing capabilities in the U.S. and deepen collaboration with local stakeholders [5][7] - The company plans to invest further in the Rockville site to expand its capacity and upgrade technology, contributing to a more resilient U.S. supply chain for critical biologic medicines [2][7] - Samsung Biologics has a proven track record of operational excellence, with significant capacity across its Bio Campus I and II, totaling 785,000 liters [4][8] Industry Context - GSK's divestment of the Rockville site is aimed at securing the manufacture of important medicines on U.S. soil, aligning with its commitment to invest USD 30 billion in R&D and manufacturing in the U.S. over the next five years [6] - The acquisition underscores the long-term dedication of Samsung Biologics to the U.S. biopharmaceutical industry and supply chain [7]